N. Zacarias

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.

J. Storek, P. Duggan, N. Bahlis, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.

A. Magliocco, F. Naveed, J. Storek, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

W. Irish, J. Storek, P. Duggan, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.

J. Storek, P. Duggan, N. Bahlis, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG

J. Storek, P. Duggan, N. Bahlis, 2011, Bone Marrow Transplantation.